Semaglutide — sold as Wegovy for weight management and Ozempic for type 2 diabetes — reduced knee osteoarthritis pain substantially more than placebo in a 68-week randomized trial. The likely reason is the weight that came off, not any direct effect on cartilage. At the same time, many people starting a GLP-1 drug report new aches in the knees, hips, shoulders and back. Both things can be true. This page pulls them apart. It covers what the trial evidence supports and what the drug labels actually say about joint pain. It also covers the most likely cause of new soreness in someone losing weight fast.
How do Ozempic and Wegovy work?
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are injectable incretin drugs (drugs that copy gut hormones). They slow how fast the stomach empties. They quiet hunger signals in the brain. And they raise insulin release when blood sugar is high. Those are metabolic actions, not joint actions. No direct effect on human cartilage, joint lining or the bone under the cartilage has been shown. Whatever these drugs do for an arthritic knee, the proven route is indirect. It runs through body weight, body makeup, and the low-grade inflammation that comes with extra fat. That caps what to expect. A GLP-1 drug is not a joint drug. It is a metabolic drug whose effects reach the joint down the line.
Do Ozempic and Wegovy help knee arthritis pain?
The strongest data come from STEP 9, a 68-week double-blind trial at 61 sites in 11 countries. It enrolled 407 adults with a BMI of 30 or higher. All had moderate knee osteoarthritis confirmed on X-ray, with at least moderate pain. They were randomized 2:1 to weekly semaglutide 2.4 mg or placebo. Both groups got coaching on physical activity and a lower-calorie diet.1
- Body weight fell 13.7% with semaglutide versus 3.2% with placebo.
- WOMAC pain scores fell 41.7 points versus 27.5 points. The scale runs 0–100, higher is worse, and the average start was 70.9.
- SF-36 physical function improved 12.0 points versus 6.5 points.
Two things stand out. First, the placebo group improved a lot: 27.5 points. That is what diet coaching, activity coaching, regression to the mean and the placebo response add up to in a knee OA trial. The drug’s extra edge was about 14 points, not 42. Second, serious side effects were similar between groups. But 6.7% of the semaglutide group quit for good because of side effects, versus 3.0% on placebo. Most were stomach and gut problems.1
A 2025 network meta-analysis pooled 56 obesity-drug trials with 60,307 patients. It named semaglutide as the obesity drug with a proven drop in knee osteoarthritis pain.4 That rests on the same STEP 9 result, not a separate repeat of it. An independent osteoarthritis year-in-review called the STEP 9 result substantial. It saw a possible but unconfirmed effect on the disease itself, working through weight loss.9 That is the honest framing. Symptom relief is established. Changing the joint’s structure is not.
How does losing weight reduce knee pain?
Two mechanisms, both measured directly, not assumed.
Mechanical. Researchers studied how 142 overweight and obese older adults with knee OA walked, using three-dimensional gait analysis. Each 1 kg of body weight lost was associated with about a 40 N drop in peak knee squeeze force while walking. That is about a fourfold cut in joint load for each unit of weight.2 Multiply that across thousands of steps a day, and the total unloading is not trivial.
Inflammatory. The IDEA trial randomized 454 adults with knee OA to intensive diet, exercise, or both for 18 months. Both groups with diet had lower blood interleukin-6 (an inflammation marker) than exercise alone. The diet-only group had lower knee squeeze force than exercise alone. Diet plus exercise gave the best pain and function scores of the three.3 Body fat is active tissue. Cutting it lowers the inflammation signals that make an already irritated joint more sensitive.
Note the shape of that result. Diet did the unloading, but diet plus exercise did the most for pain. Weight loss that does not keep muscle is the weaker plan. That leads to the second half of this question.
Does Wegovy cause joint pain or arthritis?
Start with the FDA record, because anyone can check it. The current FDA prescribing information for Wegovy lists no arthralgia, joint pain, osteoarthritis or myalgia (muscle pain). They are not in the trial side-effects table. They are not in the section on reports after approval. The same is true of the current Ozempic and Zepbound labels.7 Whatever joint pain people feel on these drugs, it has not met the bar for a labeled side effect.
There is a widely cited joint-pain warning in diabetes medicine. But it belongs to a different drug class. DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin) carry a Warnings and Precautions section for “Severe and Disabling Arthralgia,” which describes reports after approval. Pain started anywhere from one day to years after the drug began. It eased when the drug stopped. It came back when the same or another DPP-4 inhibitor was restarted.8 These are pills that raise your own GLP-1 levels indirectly. They are not GLP-1 agonists, and the two get mixed up constantly.
Drug-safety data draw the same line. One analysis looked at 15,052 muscle and bone side-effect reports in the FDA Adverse Event Reporting System. Overall, incretin drugs showed no signal at the body-system level. Looking at single terms, GLP-1 receptor agonists were associated with back pain and myalgia. Tirzepatide was tied to muscle atrophy (muscle wasting). The osteoarthritis and arthritis signals belonged to DPP-4 inhibitors. Median time to onset for GLP-1 and tirzepatide reports was 30 days or less.6
Voluntary reports cannot prove cause. And the people taking these drugs already have high rates of osteoarthritis. Some of what gets reported would have happened anyway. But the pattern tells you something. The early complaints are about muscle and soft tissue, not the joints themselves.
The muscle problem is the most plausible explanation
A 2026 systematic review in Annals of Internal Medicine looked at body makeup across 35 randomized trials of liraglutide, semaglutide, tirzepatide or dulaglutide. The median share of weight lost from muscle-related measures was 28.3% (IQR 15.9–39.9%). About two thirds of the incretin treatments passed the preset mark of about 25%. Most important, no study reported an objective physical function outcome. Nobody measured whether these patients got weaker.5
This is the mechanism that fits the complaints. Muscle is central to a knee. Body makeup, meaning high fat mass plus low lean mass, has been named as a factor in osteoarthritis severity and physical function,9 and more thigh muscle mass tracks with lower knee osteoarthritis risk. Picture someone who drops 30 pounds in six months on a steep calorie cut, without strength training or enough protein. The joint now carries less load. But part of the muscle that steadies it and brakes it is gone. New aching in the knees, hips and low back a few weeks in fits that trade. It does not fit a drug attacking cartilage. A dulled appetite also cuts protein, fluid and vitamin and mineral intake just as tissue is rebuilding. Those problems can be fixed.
How do you relieve joint pain on Ozempic or Wegovy?
- Get the joint examined. New pain in one joint with swelling, redness, locking or night pain is not about body makeup. It needs a diagnosis.
- Count protein. Losing weight on a dulled appetite without planned protein intake is how lean mass goes.
- Load the muscle. Strength training is the standard countermeasure. IDEA showed why it matters for pain: adding exercise to diet beat diet alone on both pain and function.3
- Watch the size of the deficit, not just the scale. A meta-analysis looked at strength-training trials done during a calorie cut. Lean-mass gains were smaller than in training without a cut. Cuts beyond about 500 kcal a day blocked lean-mass gains. Strength gains mostly held up.11
- Check the rest of the list. If you also take a DPP-4 inhibitor, that class carries a labeled joint-pain warning.8
What weight loss will not fix
STEP 9 enrolled people with moderate knee OA on X-ray. Some knees have advanced damage, poor alignment, a torn meniscus or bone-on-bone joint space loss. Such a knee does not become normal at a lower weight. It becomes a damaged knee carrying less load. That is real relief, and it is not reversal. Nothing in the trial data shows these drugs regrow cartilage. When pain lasts despite good metabolic progress, the question is what is making the signal in that joint. That is a diagnosis question, not a weight question. Other drivers of persistent pain often sit alongside a bad knee and get blamed on it by default.
If you are in the St. Louis area
Padda Institute looks at knee osteoarthritis together with the metabolic picture, because the two interact. When conservative (non-surgical) care and weight control still leave a knee painful, options include genicular nerve blocks as a diagnostic step, genicular radiofrequency ablation to quiet the pain nerves that supply the joint capsule, and viscosupplementation. Dr. Gurpreet Singh Padda, MD, MBA, MHP practices at 4477 Woodson Rd, Suite 100, St. Louis, MO 63134 and at 12174 Natural Bridge Rd, St. Louis, MO 63044. Call (314) 481-5000 or request an appointment.
Frequently asked questions
Is Wegovy approved to treat arthritis?
No. Knee osteoarthritis is not an approved use, and the FDA label makes no osteoarthritis claim.7 The pain benefit in STEP 9 is best seen as a result of weight loss. That is why it belongs in a metabolic and lifestyle medicine plan, not in arthritis treatment.
Can Wegovy cause arthritis?
There is no evidence that it causes osteoarthritis or inflammatory arthritis. Neither arthralgia nor arthritis appears in the current Wegovy prescribing information.7 In FDA side-effect reports, arthritis signals cluster with DPP-4 inhibitors, a different class.6 New joint symptoms during fast weight loss fit muscle loss and lost fitness better. That is why structured lifestyle medicine with strength training belongs in the plan from the start.
How much weight loss does it take to notice a difference in the knee?
Joint load changes right away and in step with body weight. So small losses lighten the joint before they look big on a scale.2 But the trials that showed clear symptom relief went well past small. Average weight loss was 13.7% in STEP 9 and 11.4% in the diet-plus-exercise group of IDEA.1,3 That is the reason for pairing medical weight loss with joint-directed care.
Will the joint pain come back if I stop the medication?
In the STEP 1 trial extension, semaglutide and the lifestyle program were stopped. In the next year, people regained about two thirds of their lost weight. Most heart and metabolic gains drifted back toward where they started.10 The joint benefit comes from load and inflammation, not a lasting change to the joint. So symptoms tend to follow the weight. Regaining muscle is not automatic either. Plan the exit before you need it. See what to expect when stopping Ozempic.
Does tirzepatide (Mounjaro, Zepbound) do the same thing for knees?
Tirzepatide brings equal or greater weight loss. But it has not been tested in its own knee osteoarthritis trial the way semaglutide was. So the joint evidence is not the same. In side-effect reports it carried a muscle-atrophy signal.6 For a comparison, see how Mounjaro compares to other diabetes weight-loss drugs.
What if my knee still hurts after I lose the weight?
Then the source of the pain needs to be found, not more weight lost. A diagnostic genicular nerve block shows whether the pain nerves of the joint capsule carry the signal. That decides whether genicular nerve ablation for knee osteoarthritis makes sense. Raising opioid doses is not the answer. The practice’s position is laid out in its opioid stewardship policy.
Why do my joints hurt after starting Ozempic or Wegovy?
The most likely reason is muscle, not cartilage. Across 35 trials of incretin drugs, a median 28.3% of the weight lost came from muscle-related tissue. A dulled appetite also cuts protein and fluid intake. Losing the muscle that steadies a knee or hip can leave it aching a few weeks in. A single swollen, red or locking joint is a different problem and needs an exam.
Does Ozempic cause muscle pain?
It may. In FDA side-effect reports, GLP-1 drugs were linked with back pain and muscle aches. Tirzepatide was linked with muscle atrophy. Median onset was 30 days or less. Voluntary reports cannot prove the drug caused the pain. Muscle pain is not a labeled side effect of Ozempic or Wegovy. Counting protein and adding strength training are the practical countermeasures.
Can Ozempic reverse knee arthritis?
No. Nothing in the trial data shows these drugs regrow cartilage. The STEP 9 trial enrolled people with moderate knee arthritis. Their pain improved as the knee carried less weight. A knee with advanced damage, bone-on-bone joint space loss or a meniscus problem stays damaged. It just carries less load. That is real relief, and it is not reversal.
Sources
- Bliddal H, Bays H, Czernichow S, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024;391(17):1573-1583. PMID 39476339
- Messier SP, Gutekunst DJ, Davis C, DeVita P. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum. 2005;52(7):2026-2032. PMID 15986358
- Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA. 2013;310(12):1263-1273. PMID 24065013
- McGowan B, Ciudin A, Baker JL, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med. 2025;31(10):3317-3329. PMID 41039116
- Batsis JA, Gavras A, Gross DC, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review. Ann Intern Med. 2026;179(7):996-1013. PMID 41996180
- Guo M, Chen S, Dong H, et al. Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(8):11975-11991. PMID 41748946
- Novo Nordisk. WEGOVY (semaglutide) injection, solution — full prescribing information, label version 19, published June 30, 2026. DailyMed, U.S. National Library of Medicine. DailyMed. Novo Nordisk. OZEMPIC (semaglutide) injection, solution — full prescribing information, label version 20, published June 10, 2026. DailyMed. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, solution — full prescribing information, label version 38, published May 6, 2026. DailyMed
- Merck Sharp & Dohme LLC. JANUVIA (sitagliptin) tablets — full prescribing information, section 5.6, Severe and Disabling Arthralgia. DailyMed, U.S. National Library of Medicine. Label version 71, published November 17, 2025. DailyMed
- Dell’Isola A, Recenti F, Giardulli B, Lawford BJ, Kiadaliri A. Osteoarthritis year in review 2025: Epidemiology and therapy. Osteoarthritis Cartilage. 2025;33(11):1300-1306. PMID 40914550
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID 35441470
- Murphy C, Koehler K. Energy deficiency impairs resistance training gains in lean mass but not strength: A meta-analysis and meta-regression. Scand J Med Sci Sports. 2022;32(1):125-137. PMID 34623696
Dr. Gurpreet Singh Padda, MD, MBA, MHP
